Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
75,602,672
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
39,699,603
-
Shares change
-
+3,734,870
-
Total reported value, excl. options
-
$2,112,018,735
-
Value change
-
+$205,833,024
-
Put/Call ratio
-
19%
-
Number of buys
-
88
-
Number of sells
-
-28
-
Price
-
$53.2
Significant Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q2 2021
134 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q2 2021.
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39,699,603 shares
of 75,602,672 outstanding shares and own 52.51% of the company stock.
Largest 10 shareholders include FMR LLC (6,662,225 shares), Matrix Capital Management Company, LP (4,100,739 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,259,568 shares), VANGUARD GROUP INC (2,834,824 shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2,664,409 shares), VIKING GLOBAL INVESTORS LP (2,399,284 shares), BlackRock Inc. (2,320,116 shares), Avidity Partners Management LP (2,160,000 shares), PRIMECAP MANAGEMENT CO/CA/ (1,348,610 shares), and STATE STREET CORP (1,339,340 shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.